Completed
Phase 4 Study to Evaluate Treatment Optimization With Once-daily Insulin Glargine 300 U/mL
NCT03406000
- Conditions
- Autoimmune Diseases, Diabetes Mellitus, Diabetes Mellitus, Type 1, +6 more
- Locations
-
- Investigational Site Number 076013 Campinas, Brazil
- Investigational Site Number 076016 Curitiba, Brazil
- Investigational Site Number 076007 Curitiba, Brazil
- Investigational Site Number 076005 Fortaleza, Brazil